Latest News & Features
Big Pharma
The UK health secretary has been urged by a health campaigning group to issue a compulsory licence for a breast cancer patent owned by Swiss pharmaceutical company Roche. 1 October 2015
Big Pharma
The Warner-Lambert v Actavis case concerning second medical use patents has resulted in a carefully considered judgment and there are some clear lessons to be learnt, says Arty Rajendra of Rouse Legal. 1 October 2015
Africa
The international police organisation Interpol plays a vital role in connecting law enforcement and health authorities around the world in the fight against pharmaceutical crime. Aline Plançon reports. 1 October 2015
Americas
A US presidential hopeful for the Democratic Party has urged the US to support a request that would permanently free poor countries from their responsibility to grant patent protection for drugs. 30 September 2015
Americas
Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital to invalidate a patent covering its Combigan drug after the Patent Trial and Appeal Board opted not to institute an inter partes review. 29 September 2015
Asia-Pacific
A Japanese lawyer has described a ruling by the Supreme Court of Japan as a “death sentence” for product-by-process patents and said it is a good time for drugs companies to challenge rivals’ patents. 29 September 2015
Americas
Biopharmaceutical company Celgene has reiterated its stance on the inter partes review petitions filed by hedge fund manager Kyle Bass and has hinted it will appeal against a recent unfavourable decision. 29 September 2015
Americas
The US Patent and Trademark Office has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs. 28 September 2015
Americas
Concern surrounding how the Unified Patent Court will operate echoes the worry that US patent owners had ahead of the Patent Trial and Appeal Board’s implementation, a US law firm has observed. 28 September 2015
Big Pharma
A counsel for pharmaceutical company Novartis has said he “embraces” the Unified Patent Court, but has concerns about securing preliminary injunctions and the harmonisation of supplementary protection certificates under the agreement. 28 September 2015